Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents

Neurochemistry International

Volumn 59, Issue 6, 2011, Pages 925-935

  Gyertyán, István ^a   Kiss, Béla ^a   Sághy, Katalin ^a   Laszy, Judit ^a   Szabó, Györgyi ^a   Szabados, Tamás ^a   Gémesi, Larisza I ^a   Pásztor, Gabriella ^a   Zájer Balázs, Mária ^a   Kapás, Margit ^a   Csongor, Éva Ágai ^a   Domány, György ^a   Tihanyi, Károly ^a   Szombathelyi, Zsolt ^a  

^a Pharmacology and Drug Safety Research   (Hungary)

Author keywords

Atypical antipsychotic; Cariprazine; Cognitive improvement; D 3 D2 partial agonist; Dopamine D3 receptor; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; CARIPRAZINE; DIZOCILPINE; DOPAMINE 3 RECEPTOR; OLANZAPINE; PHENCYCLIDINE; RISPERIDONE; SCOPOLAMINE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; AVOIDANCE BEHAVIOR; BINDING AFFINITY; BLOOD BRAIN BARRIER; CEREBELLUM; COGNITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG INHIBITION; DRUG RECEPTOR BINDING; HYPERACTIVITY; IN VIVO STUDY; LEARNING; LOCOMOTION; MALE; MOTOR ACTIVITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; TASK PERFORMANCE;

ANIMALS; ANTIPSYCHOTIC AGENTS; DOPAMINE AGONISTS; MALE; MICE; MICE, INBRED STRAINS; NOOTROPIC AGENTS; PIPERAZINES; PROTEIN BINDING; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE D3;

MUS; RATTUS; RODENTIA;

EID: 80255138235     PISSN: 01970186     EISSN: 18729754     Source Type: Journal    
DOI: 10.1016/j.neuint.2011.07.002     Document Type: Article

References (59)

1. A. Abi-Dargham, J. Rodenhiser, D. Printz, Y. Zea-Ponce, R. Gil, L.S. Kegeles, R. Weiss, T.B. Cooper, J.J. Mann, R.L. Van Heertum, J.M. Gorman, and M. Laruelle Increased baseline occupancy of D2 receptors by dopamine in schizophrenia Proc. Natl. Acad. Sci. USA 97 2000 8104 8109 (Pubitemid 30460780)
2. D. Accili, C.S. Fishburn, J. Drago, H. Steiner, J.E. Lachowicz, B.H. Park, E.B. Gauda, E.J. Lee, M.H. Cool, D.R. Sibley, C.R. Gerfen, H. Westphal, and S. Fuchs A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice Proc. Natl. Acad. Sci. USA 93 1996 1945 1949 (Pubitemid 26079860)
3. I. al-Khatib, H.C. Karadag, and A. Ulugol The behavioral effects of MK-801 injected into nucleus accumbens and caudate-putamen of rats Pharmacol. Biochem. Behav. 52 1995 723 730
4. L.C. Amann, M.J. Gandal, T.B. Halene, R.S. Ehrlichman, S.L. White, H.S. McCarren, and S.J. Siegel Mouse behavioral endophenotypes for schizophrenia Brain Res. Bull. 83 2010 147 161
5. L. Bardin, M.S. Kleven, C. Barret-Grevoz, R. Depoortere, and A. Newman-Tancredi Antipsychotic-like vs cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5-HT1A agonist properties Neuropsychopharmacology 31 2006 1869 1879
6. Bose, A., Li, D., Migliore, R., Papadakis, K., Werner, P., Andor, G., Laszlovszky, I. The efficacy and safety of the novel antipsychotic cariprazine in acute exacerbation of schizophrenia. Poster presented at: 50th Annual Meeting of the New Clinical Data Evaluation Unit, June 14-17, 2010, Boca Raton, FL, USA.
7. L.A. Bruins Slot, C. Palmier, S. Tardif, and D. Cussac Action of novel antipsychotics at human dopamine D3 receptors coupled to G protein and ERK1/2 activation Neuropharmacology 53 2007 232 241 (Pubitemid 47187452)
8. A.K. Chaturvedi Effects of mecamylamine, nicotine, atropine and physostigmine on the phencyclidine-induced behavioral toxicity Pharmacol. Biochem. Behav. 20 1984 559 566 (Pubitemid 14138045)
9. J.G. Csernansky, M. Martin, R. Shah, A. Bertchume, J. Colvin, and H. Dong Cholinesterase inhibitors ameliorate behavioral deficits induced by MK-801 in mice Neuropsychopharmacology 30 2005 2135 2143 (Pubitemid 41643964)
10. A. DeLeon, N.C. Patel, and M.L. Crismon Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability Clin. Ther. 26 2004 649 666 (Pubitemid 38736956)
11. S.J. Finnema, B. Bang-Andersen, H.V. Wikstrom, and C. Halldin Current state of agonist radioligands for imaging of brain dopamine D2/D3 receptors in vivo with positron emission tomography Curr. Top Med. Chem. 10 2010 1477 1498
12. Gleason, S.D., Shannon, H.E., 1997. Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice. Psychopharmacology (Berl), 129, 79-84. (Pubitemid 27037454)
13. I. Gyertyan, and K. Saghy Effects of dopamine D3 receptor antagonists on spontaneous and agonist-reduced motor activity in NMRI mice and Wistar rats: comparative study with nafadotride, U 99194A and SB 277011 Behav. Pharmacol. 15 2004 253 262 (Pubitemid 39062554)
14. I. Gyertyan, and K. Saghy The selective dopamine D3 receptor antagonists, SB 277011-A and S 33084 block haloperidol-induced catalepsy in rats Eur. J. Pharmacol. 572 2007 171 174 (Pubitemid 47429649)
15. Gyertyan, I., Saghy, K., Laszy, J., Elekes, O., Kedves, R., Gemesi, L.I., Pasztor, G., Zajer-Balazs, M., Kapas, M., Agai Csongor, E., Domany, G., Kiss, B., Szombathelyi, Z., 2008. Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. behavioural characterisation of RG-15. Naunyn Schmiedebergs Arch. Pharmacol. 378, 529-539.
16. C. Halldin, L. Farde, T. Hogberg, N. Mohell, H. Hall, T. Suhara, P. Karlsson, Y. Nakashima, and C.G. Swahn Carbon-11-FLB 457: a radioligand for extrastriatal D2 dopamine receptors J. Nucl. Med. 36 1995 1275 1281
17. T. Hirose, Y. Uwahodo, S. Yamada, T. Miwa, T. Kikuchi, H. Kitagawa, K.D. Burris, C.A. Altar, and T. Nabeshima Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile J. Psychopharmacol. 18 2004 375 383 (Pubitemid 39382565)
18. S. Kapur Psychosis as a state of aberrant salience. a framework linking biology, phenomenology, and pharmacology in schizophrenia Am. J. Psychiatry 160 2003 13 23 (Pubitemid 36042420)
19. S. Kapur, and P. Seeman Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: a new hypothesis Am. J. Psychiatry 158 2001 360 369 (Pubitemid 32205190)
20. 18 F]fallypride positron emission tomography Biol. Psychiatry 68 2010 634 641
21. T. Kikuchi, K. Tottori, Y. Uwahodo, T. Hirose, T. Miwa, Y. Oshiro, and S. Morita 7-(4-[4-(2, 3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3, 4-dihydro-2(1H)-qui nolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity J. Pharmacol. Exp. Ther. 274 1995 329 336
22. B. Kiss, F. Horti, and A. Bobok In vitro and in vivo comparison of [3H](+)-PHNO and [3H]raclopride binding to rat striatum and lobes 9 and 10 of the cerebellum: a method to distinguish dopamine D3 from D2 receptor sites Synapse. 45 2011 467 478
23. B. Kiss, A. Horvath, Z. Nemethy, E. Schmidt, I. Laszlovszky, G. Bugovics, K. Fazekas, K. Hornok, S. Orosz, I. Gyertyan, E. Agai-Csongor, G. Domany, K. Tihanyi, N. Adham, and Z. Szombathelyi Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile J. Pharmacol. Exp. Ther. 333 2010 328 340
24. Kiss, B., Laszlovszky, I., Horvath, A., Nemethy, Z., Schmidt, E., Bugovics, G., Fazekas, K., Gyertyan, I., Agai-Csongor, E., Domany, G., Szombathelyi, Z., 2008. Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: I. neurochemical characterisation of RG-15. Naunyn Schmiedebergs Arch. Pharmacol. 378, 515-528.
25. K. Kitaichi, K. Yamada, T. Hasegawa, H. Furukawa, and T. Nabeshima Effects of risperidone on phencyclidine-induced behaviors: comparison with haloperidol and ritanserin Jpn. J. Pharmacol. 66 1994 181 189 (Pubitemid 24357099)
26. M.S. Kleven, C. Barret-Grevoz, L. Bruins Slot, and A. Newman-Tancredi Novel antipsychotic agents with 5-HT(1A) agonist properties: role of 5-HT(1A) receptor activation in attenuation of catalepsy induction in rats Neuropharmacology 49 2005 135 143 (Pubitemid 40933752)
27. Knesevich, M., Papadakis, K., Bose, A., Wang, Q., Korozter, A., Laszlovszky, I. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial. Poster presented at: 162nd Annual Meeting of the American Psychiatric Associaton, May 16-21, 2009. San Francisco, Ca, USA.
28. Laszy, J., Laszlovszky, I., Gyertyan, I., 2005. Dopamine D3 receptor antagonists improve the learning performance in memory-impaired rats. Psychopharmacology (Berl) 179, 567-575. (Pubitemid 40674757)
29. C. Lawler, C. Prioleau, M. Lewis, C. Mak, D. Jiang, J. Schetz, A. Gonzalez, D. Sibley, and R. Mailman Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes Neuropsychopharmacology 20 1999 612 627 (Pubitemid 29189265)
30. L. Leriche, J.C. Schwartz, and P. Sokoloff The dopamine D3 receptor mediates locomotor hyperactivity induced by NMDA receptor blockade Neuropharmacology 45 2003 174 181 (Pubitemid 36782530)
31. B. Levant Differential distribution of D3 dopamine receptors in the brains of several mammalian species Brain Res. 800 1998 269 274 (Pubitemid 28361906)
32. A. Mattsson, E. Lindqvist, S.O. Ogren, and L. Olson Increased phencyclidine-induced hyperactivity following cortical cholinergic denervation Neuroreport 16 2005 1815 1819 (Pubitemid 41547053)
33. P.N. McCormick, S. Kapur, A. Graff-Guerrero, R. Raymond, J.N. Nobrega, and A.A. Wilson The antipsychotics olanzapine, risperidone, clozapine, and haloperidol are D2-selective ex vivo but not in vitro Neuropsychopharmacology 35 2010 1826 1835
34. H.Y. Meltzer, Z. Li, Y. Kaneda, and J. Ichikawa Serotonin receptors: their key role in drugs to treat schizophrenia Prog. Neuropsychopharmacol. Biol. Psychiatry 27 2003 1159 1172 (Pubitemid 37464960)
35. V. Micale, L. Cristino, A. Tamburella, S. Petrosino, G.M. Leggio, V. Di Marzo, and F. Drago Enhanced cognitive performance of dopamine D3 receptor "knock-out" mice in the step-through passive-avoidance test: assessing the role of the endocannabinoid/endovanilloid systems Pharmacol Res. 61 2010 531 536
36. M.J. Millan, M. Brocco, A. Gobert, F. Joly, K. Bervoets, J. Rivet, A. Newman-Tancredi, V. Audinot, and S. Maurel Contrasting mechanisms of action and sensitivity to antipsychotics of phencyclidine versus amphetamine: importance of nucleus accumbens 5-HT2A sites for PCP-induced locomotion in the rat Eur. J. Neurosci. 11 1999 4419 4432 (Pubitemid 30009274)
37. Millan, M.J., Dekeyne, A., Rivet, J.M., Dubuffet, T., Lavielle, G., Brocco, M., 2000. S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: II. functional and behavioral profile compared with GR218,231 and L741,626. J. Pharmacol. Exp. Ther. 293, 1063-1073. (Pubitemid 30417877)
38. M.J. Millan, B. Di Cara, A. Dekeyne, F. Panayi, L. De Groote, D. Sicard, L. Cistarelli, R. Billiras, and A. Gobert Selective blockade of dopamine D(3) versus D(2) receptors enhances frontocortical cholinergic transmission and social memory in rats: a parallel neurochemical and behavioural analysis J. Neurochem. 100 2007 1047 1061 (Pubitemid 46213928)
39. M.J. Millan, H. Gressier, and M. Brocco The dopamine D3 receptor antagonist, (+)-S 14297, blocks the cataleptic properties of haloperidol in rats Eur. J. Pharmacol. 321 1997 R7 9
40. M.J. Millan, F. Loiseau, A. Dekeyne, A. Gobert, G. Flik, T.I. Cremers, J.M. Rivet, D. Sicard, R. Billiras, and M. Brocco S33138 (N-[4-[2-[(3aS, 9bR)-8-cyano-1, 3a, 4, 9b-tetrahydro[1] benzopyrano[3, 4-c]pyrrol-2(3H)-yl)- ethyl]phenyl-acetamide), a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: III. actions in models of therapeutic activity and induction of side effects J. Pharmacol. Exp. Ther. 324 2008 1212 1226 (Pubitemid 351397860)
41. M.J. Millan, C. Mannoury la Cour, F. Novi, R. Maggio, V. Audinot, A. Newman-Tancredi, D. Cussac, V. Pasteau, J.A. Boutin, T. Dubuffet, and G. Lavielle S33138 [N-[4-[2-[(3aS, 9bR)-8-cyano-1, 3a, 4, 9b-tetrahydro[1]- benzopyrano[3, 4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: I. receptor-binding profile and functional actions at G-protein-coupled receptors J. Pharmacol. Exp. Ther. 324 2008 587 599 (Pubitemid 351185866)
42. Millan, M.J., Seguin, L., Gobert, A., Cussac, D., Brocco, M., 2004. The role of dopamine D3 compared with D2 receptors in the control of locomotor activity: a combined behavioural and neurochemical analysis with novel, selective antagonists in rats. Psychopharmacology (Berl), 174, 341-357. (Pubitemid 39044292)
43. N.A. Moore, N.C. Tye, M.S. Axton, and F.C. Risius The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent J. Pharmacol. Exp. Ther. 262 1992 545 551
44. S. Natesan, G.E. Reckless, J.N. Nobrega, P.J. Fletcher, and S. Kapur Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models Neuropsychopharmacology 31 2006 1854 1863
45. R.E. Nordquist, C. Risterucci, J.L. Moreau, M. von Kienlin, B. Kunnecke, M. Maco, C. Freichel, C. Riemer, and W. Spooren Effects of aripiprazole/OPC- 14597 on motor activity, pharmacological models of psychosis, and brain activity in rats Neuropharmacology 54 2008 405 416
46. M.F. O'Neill, C.L. Heron-Maxwell, and G. Shaw 5-HT2 receptor antagonism reduces hyperactivity induced by amphetamine, cocaine, and MK-801 but not D1 agonist C-APB Pharmacol. Biochem. Behav. 63 1999 237 243 (Pubitemid 29234102)
47. G. Paxinos, and C. Watson The Rat Brain in Stereotaxic Coordinates, sixth ed. 2007 Academic Press Amsterdam
48. E.A. Rabiner, M. Slifstein, J. Nobrega, C. Plisson, M. Huiban, R. Raymond, M. Diwan, A.A. Wilson, P. McCormick, G. Gentile, R.N. Gunn, and M.A. Laruelle In vivo quantification of regional dopamine-D3 receptor binding potential of (+)-PHNO: Studies in non-human primates and transgenic mice Synapse 63 2009 782 793
49. C. Reavill, S.G. Taylor, M.D. Wood, T. Ashmeade, N.E. Austin, K.Y. Avenell, I. Boyfield, C.L. Branch, J. Cilia, M.C. Coldwell, M.S. Hadley, A.J. Hunter, P. Jeffrey, F. Jewitt, C.N. Johnson, D.N. Jones, A.D. Medhurst, D.N. Middlemiss, D.J. Nash, G.J. Riley, C. Routledge, G. Stemp, K.M. Thewlis, B. Trail, A.K. Vong, and J.J. Hagan Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A J. Pharmacol. Exp. Ther. 294 2000 1154 1165 (Pubitemid 30666872)
50. N.M. Richtand, S.C. Woods, S.P. Berger, and S.M. Strakowski D3 dopamine receptor, behavioral sensitization, and psychosis Neurosci. Biobehav. Rev. 25 2001 427 443 (Pubitemid 32879299)
51. A. Schotte, P.F. Janssen, W. Gommeren, W.H. Luyten, and J.E. Leysen Autoradiographic evidence for the occlusion of rat brain dopamine D3 receptors in vivo Eur. J. Pharmacol. 218 1992 373 375
52. J.C. Schwartz, J. Diaz, C. Pilon, and P. Sokoloff Possible implications of the dopamine D(3) receptor in schizophrenia and in antipsychotic drug actions Brain Res. Brain Res. Rev. 31 2000 277 287 (Pubitemid 30136182)
53. P. Seeman Dopamine D2High receptors measured ex vivo are elevated in amphetamine-sensitized animals Synapse 63 2009 186 192
54. Y.A. Su, T.M. Si, D.F. Zhou, C.M. Guo, X.D. Wang, Y. Yang, L. Shu, and J.H. Liang Risperidone attenuates MK-801-induced hyperlocomotion in mice via the blockade of serotonin 5-HT 2A/2C receptors Eur. J. Pharmacol. 564 2007 123 130 (Pubitemid 46946856)
55. S. Takahashi, K. Takagi, and K. Horikomi Effects of a novel, selective, sigma1-ligand, MS-377, on phencyclidine-induced behaviour Naunyn Schmiedebergs Arch. Pharmacol. 364 2001 81 86 (Pubitemid 32646345)
56. Trueman, R.C., Dunnett, S.B., Brooks, S.P. Operant-based instrumental learning for analysis of genetically modified models of Huntington's disease. Brain Res. Bull. 2011. doi: 10.1016/j.brainresbull.2011.03.015.
57. M.L. Wadenberg, A. Soliman, S.C. VanderSpek, and S. Kapur Dopamine D(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects Neuropsychopharmacology 25 2001 633 641 (Pubitemid 32995945)
58. N. Waters, K. Svensson, S.R. Haadsma-Svensson, M.W. Smith, and A. Carlsson The dopamine D3-receptor: a postsynaptic receptor inhibitory on rat locomotor activity J. Neural Transm. Gen. Sect. 94 1993 11 19 (Pubitemid 23330058)
59. M.D. Wood, C. Scott, K. Clarke, J. Westaway, C.H. Davies, C. Reavill, M. Hill, C. Rourke, M. Newson, D.N. Jones, I.T. Forbes, and A. Gribble Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist properties Eur. J. Pharmacol. 546 2006 88 94 (Pubitemid 44339632)